Navigation Links
Genzyme Reports Strong Second-Quarter Growth
Date:7/23/2008

cent in this year's second quarter to $34.8 million from $25.1 million in the same quarter a year ago. This growth is being driven by the expanded U.S. sales force for Seprafilm(R) adhesion barrier, which is helping to expand the product's use in gynecologic and colorectal surgery and C-section procedures.

Second-quarter revenue for the Genetics business increased 7 percent to $78.5 million from $73.7 million. This growth was driven in part by the continuing demand for prenatal screening for genetic conditions. Additionally, Genzyme experienced increased demand for its KRAS mutation testing for colorectal cancer, as recent studies have shown that identifying KRAS mutations can assist oncologists in selecting treatment for patients with colorectal cancer. This increasing recognition of the value of diagnostics in personalized medicine will continue to fuel organic growth in the Genetics business.

Oncology revenue rose in the second quarter to $33.3 million from $17.4 million based on increasing sales of Clolar and Campath(R) (alemtuzumab). The increase also reflects the addition of European sales of Clolar, which Genzyme began recording following its acquisition of Bioenvision Inc. late last year. Genzyme is working to introduce Clolar worldwide as well as expand its indications. The product is currently approved in the United States and Europe as a third-line treatment for pediatric patients with acute lymphoblastic leukemia. Genzyme is developing Clolar for use globally as a first-line therapy for adult AML and myelodysplastic syndromes, significantly larger indications that the company estimates will drive peak annual sales of the product to approximately $600 million. Last month, Genzyme reported encouraging results from its pivotal CLASSIC II trial evaluating the use of Clolar to treat older adult patients with acute myeloid leukemia. Oncology revenue also reflects growing first-line use of Campath in the treatment of patients with B-cell chronic l
'/>"/>

SOURCE Genzyme Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
2. Genzyme Begins Major Expansion of Boston Manufacturing Facility
3. Genzyme Affirms Purchase Price for Bioenvision at $5.60 Per Outstanding Share
4. Genzyme Receives Approval to Market Elaprase(R) in Japan
5. Genzyme Recognized by Scientists as a Top Employer
6. Genzyme to Participate in FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
7. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
8. Genzyme Launches Cholestagel(R) in Europe
9. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
10. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
11. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... 2, 2015 Veracyte, Inc. (NASDAQ: VCYT ... president and chief executive officer, will present at the ... 2015 at 10:30 a.m. ET in New ... audio webcast and subsequent replay may be accessed by ... available shortly after conclusion of the presentation and archived ...
(Date:9/2/2015)... ZIONA, Israel , September 2, 2015 ... BVXV) today announced the intent of the National Institute of ... Institutes of Health (NIH) within the Department of Health and ... to be held in the United States ... use of BiondVax,s universal flu vaccine candidate, Multimeric-001 (M-001), as ...
(Date:9/2/2015)... ... September 02, 2015 , ... Advancing in medical imaging processing ... sign monitoring in ICU to 3D skull printing analysis for Neurosurgery, ONYX ZEUS ... decisions with simultaneous access to high precision medical images and electronic health records. ...
(Date:9/2/2015)... ... 02, 2015 , ... Temarry Recycling's new $100,000 waste to ... process and continue to contribute to the sustainability of our natural resources. , ... process has been operating at their Mexico facility, Recicladora Temarry, for the last ...
Breaking Biology Technology:Veracyte to Present at Morgan Stanley Global Healthcare Conference 2BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 2BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 3Surgical Workstation Powered by 6th Gen. Intel® Core™ Skylake Processors 2Surgical Workstation Powered by 6th Gen. Intel® Core™ Skylake Processors 3Temarry Recycling’s New $100,000 Waste to Energy Renovation 2
... HARRISBURG, Pa., Oct. 20 PresentCare, a technology ... AdherencePlus(TM) solution, an innovative approach to assist the ... medication non-adherence. The AdherencePlus solution is comprised ... communication technology combined with unprecedented human touch. Both ...
... , ROME, October 20 ... of World Osteoporosis Day, International Osteoporosis Foundation,(IOF) CEO ... the,globe to join the fight against osteoporosis. "Osteoporosis ... afford to ignore. Immediate measures must,be taken to ...
... 19 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc.,(OTC Bulletin Board: LTUS) ("Lotus" ... and licensed national seller of pharmaceutical,products in the People,s Republic ... Lotus,s priorities for the balance of 2009 are, ... do for its most valuable customers, ...
Cached Biology Technology:Medication Adherence Technology Combines with Patient Outreach Program to Yield Healthier Populations and Reduce Healthcare Costs 2Medication Adherence Technology Combines with Patient Outreach Program to Yield Healthier Populations and Reduce Healthcare Costs 3World Osteoporosis Day Call for Immediate Action to Prevent Fractures 2Lotus Pharmaceuticals, Inc. Announces 2010 Growth Strategy 2Lotus Pharmaceuticals, Inc. Announces 2010 Growth Strategy 3Lotus Pharmaceuticals, Inc. Announces 2010 Growth Strategy 4
(Date:8/17/2015)... 17, 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market and creator of ... for Q4 2015. The new marketing campaign is being ... Amplitude Marketing Group ( http://amplitudemarketing.com/ ) and TPMG ( ... leader in retail driven marketing and brand awareness and ...
(Date:8/11/2015)... 11, 2015 Today, ZUK announced its Android ... well as expected revenues in 2015 that relate to sales of ... guidance of approximately 2,200 MSEK for 2015. Jörgen Lantto, ... prominent smartphone manufacturer in China ... selected FPC1 155 for Z1 ...
(Date:8/6/2015)... SAN JOSE, Calif. , Aug. 6, 2015 ... the leading developer of human interface solutions, today ... and TouchPad technologies on Windows 10. Microsoft leveraged ... fundamental to the operating system. ... and drivers are fully certified with Microsoft,s Precision ...
Breaking Biology News(10 mins):NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2Synaptics Chosen for Human Interface Co-Development on Windows 10 2
... VA As the Colorado River winds through the Colorado ... of sediment. This sediment which once left the river,s ... Colorado "the reddish river" is a vital component to ... of the Hoover and Glen Canyon dams, which trap the ...
... significant upgrade that would enable it to produce high-quality, ... key material by a team of researchers that includes ... Texas A&M University. The material, which converts ... to produce an image, is the result of a ...
... Vulcan mind meld to share cognition: Virginia Tech Carilion ... and hot feelings may be more intimately connected than previously ... parts, like Spock, and separate emotional parts, like Kirk. But ... , director of the Human Neuroimaging Laboratory at ...
Cached Biology News:Texas A&M research contributes to improved ultrasound imaging 2Kirk, Spock together: Putting emotion, logic into computational words 2
Phospho-Chk1 (Ser296) Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Mouse monoclonal [CRC64] to Integrin alpha 2b + beta 3 ( Abpromise for all tested applications). Antigen: Human platelets Entrez Gene ID: 23295 Swiss Protein ID: P05106...
Goat polyclonal to DDDDK tag (FITC) ( Abpromise for all tested applications)....
Sheep polyclonal to Trenbolone ( Abpromise for all tested applications). Antigen: Chemical / Small Molecule: 17 alpha Trenbolone(3)-BTG....
Biology Products: